Stock listing

NASDAQ:CTNM Contineum Therapeutics, Inc. Stock

Home listing (NASDAQ) of Contineum Therapeutics, Inc.

Follow Contineum Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CTNM

$8.68 USD -0.56 (-6.1%)

Close on Nov 20, 2026

Past year -29.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.50 – $9.09 USDNov 20, 2026
Volume
369,211 sharesNov 20, 2026
Market cap
$286.1M USDAt the close on Nov 20, 2026 · price × 32.96M shares outstanding
52-week range
$6.73 – $17.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$8.47M USDMedian day 525,811 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Contineum Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CTNM · Home$8.68 USD-0.56 (-6.1%)369,211$8.87$9.09$8.50$9.24Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CTNM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.68-0.56-6.1%$8.87$9.09$8.50369,211
$9.24-0.31-3.2%$9.85$9.85$9.23204,006
$9.55-0.12-1.2%$9.58$9.685$9.33294,107
$9.67-0.19-1.9%$9.67$9.93$9.46348,145
$9.86+0.08+0.8%$9.775$10.14$9.38265,893
$9.78-0.99-9.2%$10.71$10.89$9.74315,426
$10.77+0.21+2.0%$10.68$10.91$10.57287,645
$10.56+0.26+2.5%$10.24$10.61$10.01249,721
$10.30+0.78+8.2%$9.74$10.50$9.32264,636
$9.52+0.71+8.1%$8.96$9.79$8.59343,535
$8.81-0.98-10.0%$9.59$9.84$8.65584,009
$9.79+0.10+1.0%$10.00$10.32$9.56804,447
$9.69+0.13+1.4%$9.57$9.935$9.54525,811
$9.56+0.17+1.8%$9.46$9.64$9.13369,006
$9.39+0.06+0.6%$9.14$9.58$8.94458,621
$9.33+0.18+2.0%$9.13$9.865$9.13566,921
$9.15+0.16+1.8%$8.92$9.34$8.59570,475
$8.99+0.85+10.4%$8.18$9.12$8.02642,897
$8.14-0.17-2.0%$8.25$8.59$8.02402,682
$8.31-0.085-1.0%$8.24$8.43$8.01428,769
$8.395+0.045+0.5%$8.32$8.75$8.12498,754
$8.35-0.11-1.3%$8.49$8.79$8.151,116,729
$8.46+1.02+13.7%$7.38$8.70$7.1452,200,902
$7.44+0.36+5.1%$7.01$7.45$6.7251,796,473
$7.08-0.82-10.4%$7.87$7.87$6.951,108,100
$7.90-0.24-2.9%$8.25$8.56$7.721,018,200
$8.14-0.28-3.3%$8.21$8.796$7.961,014,500
$8.42-0.145-1.7%$8.56$8.94$8.0952,649,100
$8.565-4.815-36.0%$9.90$11.54$8.4258,463,200
$13.38+0.20+1.5%$13.17$13.86$12.94885,600
$13.18+0.45+3.5%$12.55$13.29$12.391,178,300
$12.73+0.08+0.6%$12.42$13.01$12.31707,700
$12.65-0.07-0.6%$12.88$12.88$12.17761,900
$12.72-0.40-3.0%$13.14$13.30$12.41508,400
$13.12+0.13+1.0%$13.15$13.24$12.59794,300
$12.99-0.43-3.2%$13.30$13.50$12.62774,000
$13.42+1.92+16.7%$11.59$13.55$11.591,597,800
$11.50-1.23-9.7%$12.83$13.09$10.84854,900
$12.73+0.17+1.4%$12.38$13.36$11.95534,100
$12.56+0.07+0.6%$12.57$12.88$12.10404,900
$12.49-0.02-0.2%$12.49$12.74$11.40632,200
$12.51-0.89-6.6%$13.33$13.33$12.44550,300
$13.40-0.15-1.1%$13.74$14.00$13.19770,300
$13.55+0.02+0.1%$13.69$13.89$13.44638,500
$13.53+0.32+2.4%$13.23$13.89$13.152,139,400
$13.21-0.55-4.0%$14.07$14.40$12.86580,100
$13.76-0.06-0.4%$13.97$14.60$13.70786,000
$13.82-1.00-6.7%$13.76$14.18$13.08704,600
$14.820.000.0%$14.89$15.51$14.74607,600
$14.82+0.16+1.1%$14.94$15.24$14.62165,100
$14.66-0.48-3.2%$14.97$15.22$14.61203,300
$15.14-0.80-5.0%$15.81$16.06$15.09388,800
$15.94-0.76-4.6%$16.59$16.95$15.88316,200
$16.70-0.87-5.0%$17.38$17.71$16.50346,200
$17.57+0.33+1.9%$17.39$17.79$17.03320,800
$17.24+0.69+4.2%$16.64$17.31$16.59298,600
$16.55+0.31+1.9%$16.07$16.77$15.81212,100
$16.24-0.81-4.8%$16.90$17.07$15.97360,200
$17.05-0.20-1.2%$17.06$17.40$16.93477,800
$17.25+0.23+1.4%$16.95$17.50$16.68432,400
$17.02-0.03-0.2%$16.98$17.32$16.66387,900
$17.05+0.42+2.5%$16.80$17.51$16.47724,700
$16.63-0.56-3.3%$17.00$17.24$16.23261,100
$17.19+1.17+7.3%$16.18$17.35$15.88353,900
$16.020.000.0%$15.80$16.29$15.68321,300
Ticker
NASDAQ:CTNM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Contineum Therapeutics, Inc. news

Contineum Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 46 in all · newest Nov 9, 2026 · oldest 2024
Decks
3 decks · latest July 2026

Where Contineum Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CTNM · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CTNMBOATSUnited StatesUSD

Valuation

Price/book 1.2× against a median of 3.3×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$47.86M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.53

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Contineum Therapeutics, Inc. · NASDAQ:CTNMUS$286.1MUS$47.86Mn/an/an/a1.2×n/a0.0×1.53
TRex Bio, Inc. · NASDAQ:TRXBUS$283.1MUS$205.0Mn/an/an/an/an/an/an/a
Greenwich LifeSciences, Inc. · NASDAQ:GLSIUS$282.6MUS$276.7Mn/an/an/an/an/an/a2.80
Precision BioSciences, Inc. · NASDAQ:DTILUS$282.5MUS$228.3Mn/a5.1×n/a5.5×−85.6%0.5×0.30
AP Biosciences, Inc. · TPEX:6945US$282.3MUS$215.7Mn/an/an/a4.0×n/a0.0×n/a
Fulcrum Therapeutics, Inc. · NASDAQ:FULCUS$281.8M−US$17.87Mn/an/an/a0.9×n/a0.0×0.42
Circio Holding ASA · OSL:CRNAUS$281.1MUS$225.8Mn/an/an/a5.3×n/a0.0×n/a
Relmada Therapeutics, Inc. · NASDAQ:RLMDUS$279.5MUS$77.42Mn/an/an/a1.4×n/a0.0×1.57
Benitec Biopharma Inc. · NASDAQ:BNTCUS$276.1MUS$99.78Mn/an/an/a1.6×n/a0.0×1.46
Galectin Therapeutics Inc. · NASDAQ:GALTUS$271.4MUS$293.0Mn/an/an/an/an/an/a1.20
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.2MUS$182.6Mn/a467×n/a3.3×n/a0.0×n/a
Median of the othersUS$281.5MUS$210.3M236×3.3×−85.6%0.0×1.33

Forecasts

5 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
21.43 USD · Analysts' mean
EPS, year to Dec 2026
-1.78 · 7 analysts

Team and board

Officers

OfficerRole
Carmine StengonePresident and Chief Executive Officer
Troy IgnelziChief Financial Officer, Rapport Therapeutics, Inc.
Diego MirallesPresident and Head of Research and Development, Artiva Biotherapeutics, Inc.
Evert SchimmelpenninkPresident, LENZ Therapeutics
Contineum TherapeuticsSenior Director, Investor Relations & Corporate Communications
Todd BradyDirector of Finance and Investments, Brace Pharma Capital

Board

DirectorRole
Carmine StengonePresident and Chief Executive Officer
Diego MirallesPresident and Head of Research and Development, Artiva Biotherapeutics, Inc.
Olivia WareDirector
Sarah BoyceDirector
Troy IgnelziChief Financial Officer, Rapport Therapeutics, Inc.

Events

QuarterResultsShare move
Q3 2026Nov 3, 2026 · After close+1.0%
Q2 2026Jul 30, 2026 · After close−1.6%
Q1 2026May 5, 2026 · After close+3.8%
Q4 2025Mar 5, 2026−6.6%
Q3 2025Oct 30, 2025 · After close+4.5%
Q2 2025Aug 5, 2025 · After close+5.5%
Q1 2025May 14, 2025 · After close+2.6%
Q4 2024Mar 6, 2025 · After close+5.1%
Q3 2024Nov 6, 2024 · After close+7.6%
Q2 2024Aug 13, 2024 · After close+6.2%
All 12 quarters
QuarterResultsShare move
Q1 2024May 16, 2024 · After close+3.6%
Q4 2023Feb 28, 2024

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck32 slidesJuly 2026
Technical Presentation (April 2026)Technical14 slidesApr 30, 2026
Technical Presentation (September 2025)Technical9 slidesSep 18, 2025

Open Decks

Financings

RaiseDate
Public offering of shares of Class A common stock
Made bigger: about US$90M · US$12.25 a share · Goldman Sachs & Co. LLC +5
Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead), Stifel (co-lead), RBC Capital Markets (co-lead), William Blair (co-lead), Jones
Dec 12, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Apr 4, 2024.

Price
US$16.00 a share
Shares offered
6,875,000 shares of Class A common stock
Offering size
US$110 million
Underwriters' option
Up to 1,031,250 more shares
Underwriters
Goldman Sachs & Co. LLC, Morgan Stanley, Stifel, RBC Capital Markets · In the order on the cover
Shares delivered
On or about Apr 9, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceDec 13, 2023
Filed publiclyMar 15, 2024
Amended onceApr 1, 2024
Shares registered with an exchangeApr 2, 2024
Declared effective by the SECApr 4, 2024
Final prospectus, with the priceApr 8, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Apr 8, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue0050.0M00
Cost of revenue323.0K258.0K195.0K329.0K
Gross profit-323.0K-258.0K50.0M-329.0K
Research and development51.5M38.4M27.6M16.9M22.4M
Selling, general and administrative16.5M12.5M6.32M5.83M6.29M
Operating income-68.1M-50.9M16.1M-22.7M-28.6M
Depreciation and amortization323.0K258.0K195.0K329.0K325.0K
EBITDA-67.7M-50.6M16.3M-22.4M-28.3M
Interest expense0208.0K388.0K332.0K
Income before tax-60.1M-42.3M23.2M-24.3M-29.0M
Income tax00450.0K241.0K
Net income-60.0M-42.3M22.7M-24.3M-29.0M
Earnings per share, basic-2.17-2.181.36-0.97-1.15
Earnings per share, diluted-2.17-2.180.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents75.6M21.9M15.5M5.57M4.63M
Short-term investments187.3M182.8M109.7M41.7M64.4M
Current assets267.9M206.4M127.7M48.4M69.8M
Property, plant and equipment830.0K989.0K678.0K
Total assets276.6M212.8M130.4M50.6M70.5M
Accounts payable1.02M1.81M635.0K430.0K660.0K
Current liabilities9.74M9.97M5.48M7.55M3.67M
Long-term debt3.66M
Total debt8.25M6.26M193.2M5.85M4.91M
Total liabilities15.7M14.8M5.70M11.4M8.93M
Shareholders' equity261.0M198.1M-67.9M39.3M61.6M
Shares outstanding27.7M25.9M2.35M25.1M25.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-55.3M-32.8M19.3M-20.1M-26.3M
Capital spending-231.0K-514.0K-414.0K-118.0K-168.0K
Free cash flow-55.5M-33.4M18.9M-20.2M-26.4M
Cash from investing-3.71M-69.7M-65.6M22.3M-65.0M
Cash from financing112.7M109.0M56.2M-1.24M79.8M
Share buybacks0-28.0K-4.00K0
Change in cash53.7M6.42M9.96M939.0K-11.4M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 3, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 28, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 22, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
8-K · Current reportSep 14, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2026Big-stake noticeSEC
8-K · Current reportJul 13, 2026Current reportSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 8, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
8-K · Current reportJun 26, 2026Meeting outcomeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 30, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeApr 17, 2026Big-stake noticeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
144 · Notice of proposed saleApr 6, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
424B5 · ProspectusMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
8-K · Current reportJan 26, 2026Management or board changeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
144 · Notice of proposed saleDec 23, 2025Other filingsSEC
8-K · Current reportDec 15, 2025Material contractSEC
424B5 · ProspectusDec 12, 2025Offer documentSEC
424B5 · ProspectusDec 11, 2025Offer documentSEC
8-K · Current reportDec 11, 2025Current reportSEC
8-K · Current reportNov 20, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 4, 2025Big-stake noticeSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 30, 2025ResultsSEC
8-K · Current reportSep 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 25, 2025Big-stake noticeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 27, 2025Other filingsSEC
CORRESP · Letter to the SECMay 21, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 20, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 14, 2025Offer documentSEC
8-K · Current reportMay 14, 2025ResultsSEC
S-3 · Registration statementMay 14, 2025Offer documentSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 28, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 28, 2025Insider tradeSEC
8-K · Current reportApr 28, 2025Current reportSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 17, 2025Insider tradeSEC
8-K · Current reportMar 17, 2025Management or board changeSEC
S-8 · Registration statement for employee plansMar 6, 2025Offer documentSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
144 · Notice of proposed saleNov 18, 2024Other filingsSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 31, 2024Big-stake noticeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K/A · Current report, amendedAug 14, 2024ResultsSEC
8-K · Current reportAug 13, 2024ResultsSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2024Insider tradeSEC
8-K · Current reportJun 24, 2024Management or board changeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 3, 2024Insider tradeSEC
8-K · Current reportMay 31, 2024Management or board changeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
8-K · Current reportMay 20, 2024Management or board changeSEC
10-Q · Quarterly reportMay 16, 2024Quarterly reportSEC
8-K · Current reportMay 16, 2024ResultsSEC
SC 13G · Big-stake noticeApr 15, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeApr 15, 2024Big-stake noticeSEC
4 · Change in ownershipApr 11, 2024Insider tradeSEC
SC 13G · Big-stake noticeApr 10, 2024Big-stake noticeSEC
3 · Initial statement of ownershipApr 10, 2024Insider tradeSEC
8-K · Current reportApr 9, 2024Current reportSEC
S-8 · Registration statement for employee plansApr 9, 2024Offer documentSEC
424B4 · ProspectusApr 5, 2024Offer documentSEC
SEC STAFF LETTERApr 5, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 5, 2024Other filingsSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2024Insider tradeSEC
CERT · Exchange's certificate of listingApr 4, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeApr 2, 2024Other filingsSEC
CORRESP · Letter to the SECApr 2, 2024Other filingsSEC
CORRESP · Letter to the SECApr 2, 2024Other filingsSEC
S-1/A · Registration statement, amendedApr 1, 2024Offer documentSEC
CORRESP · Letter to the SECMar 21, 2024Other filingsSEC
CORRESP · Letter to the SECMar 15, 2024Other filingsSEC
S-1 · Registration statementMar 15, 2024Offer documentSEC
UPLOAD · Letter from the SECFeb 23, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftFeb 15, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedFeb 15, 2024Offer documentSEC
UPLOAD · Letter from the SECFeb 7, 2024Other filingsSEC
SEC STAFF LETTERJan 30, 2024Other filingsSEC

This page holds 200 of 204 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Contineum Therapeutics, Inc.’s releases

Common shares
32,958,632
Fully diluted
32,958,632

Fully diluted

LineShares
Common shares32,958,632

Share count over time

CountShares
Nov 22, 202632,958,632

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Montanova Capital, LLC2.81MUS$37.8M−26,781Nov 16, 2026
Fidelity2.61MUS$35M+1.57MNov 10, 2026
BlackRock2.22MUS$29.8M+159KNov 13, 2026
Johnson & Johnson1.98MUS$26.6MNo changeOct 26, 2026
Vanguard1.77MUS$23.7M+79,202Nov 13, 2026
Janus Henderson1.72MUS$23.1MFirst reportNov 16, 2026
Franklin Templeton1.7MUS$16.7M−135KNov 12, 2026
Balyasny Asset Management L.P.1.7MUS$22.7M+172KNov 16, 2026
Trails Edge Capital Partners, LP1.69MUS$22.7MNewNov 16, 2026
Versant Venture Management, LLC1.29MUS$17.3M+750KNov 13, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Adage Capital Partners Gp, L.L.C.1.13MUS$15.1M+797KNov 16, 2026
State Street809KUS$10.9M+383KNov 12, 2026
Millennium775KUS$10.4M−156KNov 16, 2026
Geode Capital764KUS$10.3M+70,923Nov 6, 2026
Goldman Sachs754KUS$10.1M+257KNov 16, 2026
Novo Holdings A/S704KUS$9.45MNewNov 16, 2026
Sectoral Asset Management Inc690KUS$9.25M−38,000Nov 13, 2026
Hhlr Advisors, LTD.669KUS$8.98MNo changeNov 16, 2026
Red Tree Management, LLC638KUS$8.56MNo changeOct 15, 2026
Longaeva Partners L.P.626KUS$8.4M−187KNov 16, 2026
Ikarian Capital, LLC595KUS$7.98M−213KNov 16, 2026
Boxer Capital Management, LLC494KUS$6.63MNo changeNov 16, 2026
ADAR1 Capital Management, LLC385KUS$5.17M+106KNov 16, 2026
Integral Health Asset Management, LLC345KUS$4.63MNewNov 16, 2026
Squadron Capital Management LLC324KUS$4.34M+63,570Nov 16, 2026
Northern Trust279KUS$3.75M+1,298Nov 16, 2026
Schwab269KUS$3.61M+54,902Nov 16, 2026
Dimensional244KUS$3.27M+65,741Nov 4, 2026
Citadel222KUS$2.98M−175KNov 16, 2026
Sphera Funds Management LTD.221KUS$2.97M+37,904Nov 16, 2026
Palo Alto Investors LP220KUS$2.96MNewNov 16, 2026
HighVista Strategies LLC218KUS$2.92MNewNov 13, 2026
Eversept Partners, LP200KUS$2.68M+51,585Nov 16, 2026
Great Point Partners LLC186KUS$2.5M−735KNov 16, 2026
Boothbay Fund Management, LLC179KUS$2.4M−43,164Nov 16, 2026
Ameriprise178KUS$2.39M+117KNov 16, 2026
Susquehanna171KUS$2.29M+94,996Nov 16, 2026
Qube Research & Technologies Ltd168KUS$2.25M−14,725Nov 13, 2026
Silverarc Capital Management, LLC159KUS$2.13M−137KNov 12, 2026
Casdin Capital, LLC148KUS$1.99MNo changeNov 16, 2026
UBS137KUS$1.83M+6,007Nov 16, 2026
Bank of America127KUS$1.71M+80,806Nov 16, 2026
Ishara Investments LP108KUS$1.45M−97,000Nov 16, 2026
Marshall Wace, LLP103KUS$1.38M−15,082Nov 13, 2026
Y-Intercept (Hong Kong) Ltd98,428US$1.32MNewOct 16, 2026
Wellington92,580US$1.24M−58,217Nov 16, 2026
Verdad Advisers, LP90,265US$1.21M+9,251Nov 16, 2026
Acuta Capital Partners, LLC89,826US$1.21M+26,731Nov 16, 2026
Seven Fleet Capital Management LP86,654US$1.16M+26,113Nov 16, 2026
ExodusPoint Capital Management, LP76,464US$1.03MNewNov 16, 2026

This page holds 50 of 114 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
Vanguard Total Stock Market Index Fund982KUS$16.1M+71,600Jun 30, 2026
iShares Russell 2000 ETF647KUS$10.6MNewJun 30, 2026
Franklin Biotechnology Discovery Fund625KUS$9.68M−50,973Jul 31, 2026
Select Health Care Portfolio450KUS$6.07MNo changeMay 31, 2026
Vanguard Extended Market Index Fund309KUS$5.06M+35,865Jun 30, 2026
Fidelity Small Cap Index Fund295KUS$4.57MNewJul 31, 2026
Fidelity Advisor Health Care Fund280KUS$4.34MNo changeJul 31, 2026
iShares Russell 2000 Value ETF245KUS$4.01MNewJun 30, 2026
Fidelity Advisor Biotechnology Fund225KUS$3.48MNewJul 31, 2026
iShares Biotechnology ETF205KUS$3.36M+4,801Jun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Fidelity Small Cap Stock Fund177KUS$2.74MNewJul 31, 2026
Fidelity Extended Market Index Fund126KUS$1.71M+28,529May 31, 2026
Schwab U.S. Small-Cap ETF116KUS$1.56M+23,199May 31, 2026
iShares Micro-Cap ETF90,316US$1.48M+28,646Jun 30, 2026
VIP Health Care Portfolio80,000US$1.31MNo changeJun 30, 2026
Schwab Small-Cap Index Fund65,166US$1.01MNewJul 31, 2026
Dimensional U.S. Small Cap ETF54,517US$844K+15,415Jul 31, 2026
Master Small Cap Index Series50,243US$823KNewJun 30, 2026
Fidelity Total Market Index Fund46,257US$624K+12,495May 31, 2026
Small Cap Value Fund44,741US$733KNewJun 30, 2026
Avantis U.S. Small Cap Equity ETF40,696US$549K+14,517May 31, 2026
Fidelity Small Cap Value Index Fund37,643US$617KNewJun 30, 2026
Fidelity Series Total Market Index Fund37,141US$501K+10,408May 31, 2026
Nuveen Small Cap Blend Index Fund35,707US$553KNewJul 31, 2026
U.S. Micro Cap Portfolio30,840US$478K+16,004Jul 31, 2026
EQ/2000 Managed Volatility Portfolio28,634US$469KNewJun 30, 2026
Ultra-Small Company Market Fund26,900US$441KNo changeJun 30, 2026
U.S. Small Cap Portfolio26,681US$413K+14,327Jul 31, 2026
Ultra-Small Company Fund22,380US$367KNo changeJun 30, 2026
Fidelity Nasdaq Composite Index Fund19,798US$267K+2,256May 31, 2026
LVIP State Street Small-Cap Index Fund19,600US$321KNewJun 30, 2026
Vanguard Balanced Index Fund16,648US$273KNo changeJun 30, 2026
Schwab Total Stock Market Index Fund15,969US$247KNo changeJul 31, 2026
Fidelity ZERO Total Market Index Fund14,700US$228K+2,160Jul 31, 2026
Small Cap Index Fund13,854US$227KNewJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund13,802US$226KNo changeJun 30, 2026
Allspring Disciplined Small Cap Fund13,159US$216KNewJun 30, 2026
Global X Russell 2000 ETF12,794US$198KNewJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund11,320US$186K+7,908Jun 30, 2026
T. Rowe Price Extended Equity Market Index Fund11,300US$185KNo changeJun 30, 2026
Schwab U.S. Broad Market ETF10,500US$142KNo changeMay 31, 2026
Fidelity ZERO Extended Market Index Fund9,486US$147K+1,036Jul 31, 2026
MetLife Russell 2000 Index Portfolio9,324US$153KNewJun 30, 2026
ATM Small Cap Managed Volatility Portfolio8,439US$138KNewJun 30, 2026
Small-Cap Index Portfolio7,623US$125KNewJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio6,900US$113KNewJun 30, 2026
1290 VT Micro Cap Portfolio6,007US$98,455+1,652Jun 30, 2026
NVIT Small Cap Index Fund5,922US$97,062NewJun 30, 2026
Small Cap Index Trust5,759US$94,390NewJun 30, 2026
U.S. Core Equity 2 Portfolio4,969US$76,970No changeJul 31, 2026

This page holds 50 of 102 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Stengone Carmine N.
Director, Officer: CEO and President
Sale2,500USD 16.46US$41,150Sep 8, 2026
Stengone Carmine N.
Director, Officer: CEO and President
Sale2,500USD 16.01US$40,025Aug 3, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale25USD 16.00US$400Jul 9, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale1,015USD 16.00US$16,240Jul 8, 2026
Stengone Carmine N.
Director, Officer: CEO and President
Sale2,500USD 16.00US$40,000Jul 8, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale5,852USD 15.67US$91,701Jul 1, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale2,501USD 16.24US$40,616Jul 1, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale28,826USD 16.04US$462KJun 30, 2026
Stengone Carmine N.
Director, Officer: CEO and President
Sale10,000USD 16.01US$160KJun 30, 2026
Watkins Tim
Officer: CMO & Head of Development
Sale10,833USD 16.02US$174KJun 30, 2026
All 14 trades
InsiderTradeSharesPriceValueDate
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale4,170USD 13.16US$54,877Jun 1, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale3,870USD 13.06US$50,542May 1, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale300USD 13.84US$4,152May 1, 2026
Lorrain Daniel S.
Officer: Chief Scientific Officer
Sale4,170USD 13.43US$56,003Apr 6, 2026

Big stakes

HolderStakeSharesDate
FMR LLC7.90%2.61MSep 30, 2026
Balyasny Asset Management L.P.7.35%2.42MSep 30, 2026
BlackRock, Inc.6.30%2.05MJun 30, 2026
Johnson & Johnson Innovation - JJDC, Inc.5.60%1.98MNov 3, 2026
Franklin Resources Inc5.20%1.7MSep 30, 2026
Squadron Capital Management LLC5.10%1.7MOct 21, 2026
Trails Edge Capital Partners, LP5.10%1.68MSep 22, 2026
Janus Henderson Group PLC4.60%1.72MSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Sarah Boyce
Other companies: Atrium Therapeutics, Inc. (Chair · Since at least Feb 26, 2026); Avidity Biosciences, Inc (President and CEO, Director · Since at least Jun 11, 2020); OmniAb, Inc. (Director · Nov 1, 2022 – Jun 18, 2024 · Past); Berkeley Lights Inc (Director · Jul 16, 2020 – May 14, 2021 · Past); Ligand Pharmaceuticals Incorporated (Director · Oct 15, 2019 – Jun 10, 2022 · Past); Akcea Therapeutics Inc (President, Director · Apr 17, 2018 – Jul 15, 2019 · Past); Ionis Pharmaceuticals, Inc. (Chief Business Officer · Jan 1, 2015 – Jan 15, 2018 · Past)
Director · Since at least Jun 24, 2024
Todd C. Brady
Other companies: Aldeyra Therapeutics, Inc. (Chief Executive Officer, President & Director · Since at least May 1, 2014); Evoke Pharma Inc (Director · Since at least Sep 24, 2013); Avidity Biosciences, Inc (Director · Jun 11, 2020 – Jun 11, 2020 · Past); Cocrystal Pharma, Inc. (Director · Feb 1, 2019 – Feb 1, 2019 · Past); Spring Bank Pharmaceuticals Inc (Director · Jul 28, 2016 – Sep 30, 2020 · Past); Outlook Therapeutics, Inc. (Director · May 12, 2016 – Oct 26, 2017 · Past)
Director · Since at least Apr 4, 2024
Troy Ignelzi
Other companies: Harmony Biosciences Holdings, Inc. (Director · Since at least Apr 2, 2026); Rapport Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 6, 2024); CinCor Pharma Inc (Director · Jan 6, 2022 – Feb 24, 2023 · Past); Karuna Therapeutics Inc (Chief Financial Officer · Jun 27, 2019 – Aug 22, 2023 · Past); Scpharmaceuticals Inc (Chief Financial Officer · Nov 16, 2017 – Jan 17, 2018 · Past)
Chief Financial Officer, Rapport Therapeutics, Inc. · Since at least May 20, 2024
Evert Schimmelpennink
Other companies: LENZ Therapeutics, Inc. (President, Chief Executive Officer, Secretary and Director · Since at least Mar 21, 2024); iBio, Inc. (Director · Since at least Jun 7, 2021); Pfenex Inc (See Remarks, Director · Aug 3, 2017 – Oct 1, 2020 · Past)
President, LENZ Therapeutics · Since at least Apr 4, 2024
Gines Diego Miralles
Other companies: Artiva Biotherapeutics, Inc. (President & Head of R&D · Since at least Jul 18, 2024); NeuBase Therapeutics Inc (Director · Jul 12, 2019 – Sep 9, 2020 · Past)
Director · Since at least Mar 14, 2025
Lori Lyons-Williams
Other companies: RAPT Therapeutics Inc (Director · Since at least Nov 9, 2021); Five Prime Therapeutics Inc (Director · Jun 23, 2019 – Apr 16, 2021 · Past)
Director · Since at least Apr 4, 2024
Olivia Ware
Other companies: Arcellx Inc (Director · Since at least May 16, 2022); Revance Therapeutics, Inc. (Director · Mar 6, 2021 – Feb 4, 2025 · Past)
Director · Since at least Apr 4, 2024
Carmine Stengone
Other companies: Kiora Pharmaceuticals, Inc. (Director · Since at least Aug 1, 2023)
President and Chief Executive Officer · Since at least Apr 4, 2024
Diego Miralles
Other companies: Artiva Biotherapeutics, Inc. (Director · Since May 19, 2026)
President and Head of Research and Development, Artiva Biotherapeutics, Inc. · Since at least Mar 17, 2025
John Stephen Healy
Other companies: Tyra Biosciences, Inc. (General Counsel and Secretary · Mar 1, 2022 – Mar 1, 2022 · Past)
General Counsel and Corp Sec · Since at least May 30, 2024
All 15 people
PersonSeat
Contineum TherapeuticsSenior Director, Investor Relations & Corporate Communications · Since at least Sep 14, 2026
Daniel S LorrainChief Scientific Officer · Since at least Apr 4, 2024
Peter T SloverChief Financial Officer · Since at least Apr 4, 2024
Stephen L HuhnCMO & Sr VP, Clinical Dev. · Apr 4, 2024 – Jan 31, 2025 · Past
Tim WatkinsCMO & Head of Development · Since at least Apr 28, 2025

Open People

Log in to ask 6ix AI your own questions about Contineum Therapeutics, Inc.